REHAN SALEEM: Open Payments
NPI 1447216668 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$12,593 in 287 payments from 18 companies in 2025. Trend: 2023 $3,479 · 2024 $4,016 · 2025 $12,593
Speaker / faculty: $8,000Food & beverage: $4,516Education: $66Travel & lodging: $11
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 38 | $8,615 |
| Vanda Pharmaceuticals Inc. | 29 | $537 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 36 | $446 |
| Otsuka America Pharmaceutical, Inc. | 25 | $397 |
| Alkermes, Inc. | 16 | $333 |
| Neurocrine BioSciences, Inc. | 16 | $302 |
| Lundbeck LLC | 17 | $279 |
| E.R. Squibb & Sons, L.L.C. | 14 | $268 |
| Teva Pharmaceuticals USA, Inc. | 17 | $253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $215 |
Products named: VRAYLAR, REXULTI, FANAPT, CAPLYTA, ARISTADA, INGREZZA, COBENFY, TRINTELLIX.
Industry payments across VA — which companies pay providers there.
